| Page 1990 | Kisaco Research
 

Nutritional Health

Nutritional Health

Nutritional Health

 

Diagnostics

Diagnostics

Diagnostics

 

Pain & Inflammation

Pain & Inflammation

Pain & Inflammation

 

Allergic Diseases and Allergy

Allergic Diseases and Allergy

Allergic Diseases and Allergy

 

Metabolic Disease

Metabolic Disease

Metabolic Disease

 

Infectious Disease

Infectious Disease

Infectious Disease

 

Antibiotic Alternatives

Antibiotic Alternatives

Antibiotic Alternatives

 

Immunology

Immunology

Immunology

 

Oncology

Oncology

Oncology

 

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry.

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry. At Merck and then Merial he was the project leader for two global programs that led to new pain management products for osteoarthritis in dogs and horses.  He subsequently held leadership roles for pharmaceutical R&D and project & portfolio management before moving to Abbott Animal Health where he was head of R&D & medical affairs.  Peter received his BA and DVM from the University of Minnesota and completed a large animal surgical residency, MS and PhD at the University of Wisconsin-Madison.